Research and Markets has announced the addition of the "Malignant
Glioma - Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2017" drug pipelines to their offering.
Malignant Glioma - Global API Manufacturers, Marketed and Phase III
Drugs Landscape, 2017, provides comprehensive insights about the
marketed drugs, drug sales, Phase III pipeline drugs and their API
Manufacturers across the globe.
A key objective of the Malignant Glioma Report is to understand the
market and pipeline status of the drugs around the Malignant Glioma to
explore the generic development opportunities, licensing opportunities
and to gain competitive advantage on designing pipeline strategies. The
Report provides the historical and forecasted sales of the drugs till
The Malignant Glioma Report gives insights into patents providing the
patent protection data and marketing exclusivity of all the drugs across
the Malignant Glioma.
While the leading brands, companies and chemicals are considered
thoroughly, the report also provides details on the Global API
Manufacturers across the globe covering Drug Master Filings of US,
Europe and API Manufacturers in Asia specifically China and India.
Key Topics Covered:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Malignant Glioma
7. Phase III Drugs for Malignant Glioma
8. Discontinued Drugs for Malignant Glioma
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/c8kg5k/malignant_glioma
View source version on businesswire.com: http://www.businesswire.com/news/home/20170217005542/en/
Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor
E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call
1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Related